The study , published in the April edition of the Proceedings of the National Academy of Sciences that in bladder cancer the SRC gene may help rather than hinder the natural ability of cells aggressive aggressive tumor growth it. We found that SRC makes a recently discovered metastasis suppressor gene called RhoGDI2 it slow stronger bladder cancer changed ability to metastasize, says the author Dan Theodorescu, Professor of Urologic Oncology and Molecular Physiology at UVA School of Medicine..
Furthermore, they found that reduced SRC levels and significant levels of the metastasis suppressor gene, RhoGD12, appear mutually exclusive in individual tumors evidence that both genes. Likely in the process which are to suppress bladder cancer metastasis involved ‘Our findings have important implications for the use of targeted therapeutics that inhibit SRC bladder cancer and highlight the general importance of personalizing therapy in cancer,’says Theodorescu. ‘Our data suggest suggest caution for its use in the treatment of bladder cancer, and further studies conducted to be performed to define the impact of this form of therapy for bladder cancer.
For more information, visit the Premier Safety Institute.New Discovery doubts power Bladder Cancer TreatmentResearchers at the University of Virginia Health System have found that one of the genes commonly believed to promote the growth and spread of some types of cancer, is in fact advantageous bladder cancer an important discovery could significantly change the way bladder cancer in the future be treated..Takeda converted to applications the next six months the next six months. These drug application have been obtained in response to a complete response letter from FDA on 25 Takeda April 2015 will be returned. Fixed-dose combination Furiex agreement with Takeda Furiex is entitled to receive a $ 25 million milestone payment for the approval of the first of those two NDAs, as well as potential royalties and revenue – based milestones.
FDA.. Alogliptin and of pioglitazone is a fixed combination therapy to the treatment of type 2 diabetic which together alogliptin and of pioglitazone reported in a single tablet. A thiazolidinedione of pioglitazone which directly targeted insulin resistance, a condition where said body efficiently efficiently Use this the insulin it produces blood sugar blood sugar levels. There currently in adults to in adults for the treatment of type 2 diabetes mellitus in addition to diet and exercise. O new drug application for the alogliptin and pioglitazone fixed-dose combination has authorized in July 2011 by the Japanese Ministry of Health, Labour and Welfare for treatment of type 2 diabetes and Takeda currently selling which therapy under the brand name LIOVEL on this market. ‘We are pleased to Takeda has taken over this important step for which resubmission to the alogliptin NDA This resubmission have important advance in the direction approved of alogliptin a monotherapy,’said Fred Eshelman, chairman of Furiex.
$ 376 000 Takeda resubmission of the Alogliptin Alogliptin and the fixed combination of pioglitazone and drug application with U.S.